Granholm, Anders
Kjær, Maj-Brit Nørregaard
Munch, Marie Warrer
Myatra, Sheila Nainan
Vijayaraghavan, Bharath Kumar Tirupakuzhi
Cronhjort, Maria
Wahlin, Rebecka Rubenson
Jakob, Stephan M.
Cioccari, Luca
Vesterlund, Gitte Kingo
Meyhoff, Tine Sylvest
Helleberg, Marie
Møller, Morten Hylander
Benfield, Thomas
Venkatesh, Balasubramanian
Hammond, Naomi E.
Micallef, Sharon
Bassi, Abhinav
John, Oommen
Jha, Vivekanand
Kristiansen, Klaus Tjelle
Ulrik, Charlotte Suppli
Jørgensen, Vibeke Lind
Smitt, Margit
Bestle, Morten H.
Andreasen, Anne Sofie
Poulsen, Lone Musaeus
Rasmussen, Bodil Steen
Brøchner, Anne Craveiro
Strøm, Thomas
Møller, Anders
Khan, Mohd Saif
Padmanaban, Ajay
Divatia, Jigeeshu Vasishtha
Saseedharan, Sanjith
Borawake, Kapil
Kapadia, Farhad
Dixit, Subhal
Chawla, Rajesh
Shukla, Urvi
Amin, Pravin
Chew, Michelle S.
Wamberg, Christian Aage
Bose, Neeta
Shah, Mehul S.
Darfelt, Iben S.
Gluud, Christian
Lange, Theis
Perner, Anders http://orcid.org/0000-0002-4668-0123
Clinical trials referenced in this document:
Documents that mention this clinical trial
Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID STEROID 2 randomized trial
https://doi.org/10.1007/s43678-022-00293-1
Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia
https://doi.org/10.1007/s00134-022-06677-2
Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial
https://doi.org/10.1007/s00134-021-06573-1
Funding for this research was provided by:
Novo Nordisk Fonden (0062998)
Rigshospitalet (E-22703-06)
Article History
Received: 7 February 2022
Accepted: 10 March 2022
First Online: 31 March 2022
Declarations
:
: AG, MBNK, MWM, GKV, TSM, MHM and AP are affiliated with the Dept. of Intensive Care, Rigshospitalet, which has received grants for research from Pfizer, Fresenius Kabi, AM Pharma, and Sygeforsikringen ‘danmark’ outside the submitted work. MH has participated in advisory boards for AstraZeneca, GSK, Gilead, MSD, Roche and Sobi and received speaker’s honoraria from GSK and Gilead. TB reports grants from Novo Nordisk Foundation, grants from Simonsen Foundation, grants and personal fees from GSK, grants and personal fees from Pfizer, personal fees from Astra Zeneca, personal fees from Janssen, personal fees from Boehringer Ingelheim, grants and personal fees from Gilead, personal fees from MSD, grants from Lundbeck Foundation, grants from Kai Hansen Foundation, personal fees from Pentabase ApS, grants from Erik and Susanna Olesen’s Charitable Fund, outside the submitted work. SMJ and LC are affiliated with Inselspital, Bern University Hospital, which has received grants from Edwards Lifesciences Services GmbH, Phagenesis Limited, and Nestlé outside the submitted work. JVD has received personal fees (paid to his institution) from Edwards India outside the submitted work. VJ has received grant funding from GSK, Baxter Healthcare, and Biocon and honoraria from Boehringer Ingelheim, Astra Zeneca, Baxter Healthcare, Bayer, NephroPlus and Zydus Cadilla, under the policy of all monies being paid to the organization.
: The trial protocol was approved by the Ethics Committee of the Capital Region of Denmark with additional national/local approvals as required; additional details on approvals are presented in the protocol (ESM 1) [CitationRef removed].
: Consent was obtained from patients or legal surrogates according to applicable laws and regulations in the participating countries. Enrolment according to an emergency procedure (i.e., consent from a doctor independent of the trial followed by consent from relatives and/or patients) was allowed at many sites; additional details were presented in the primary report [CitationRef removed].
: All authors approved the manuscript for publication.
Free to read: This content has been made available to all.